Angiotech Pharmaceuticals

MedCity Influencers

Stent drug maker Angiotech delisted from NASDAQ

Angiotech staked its fortunes to Boston Scientific Corp. (NYSEBSX) and the Taxus drug-eluting stent for which Angiotech makes the drug paclitaxel, but it has struggled with sales of the stent in the cellar and still falling. Royalties from Taxus sales — Angiotech pulls in about 6 percent of net sales worldwide — were off by 50 percent during the three months ended on June 30, and 56 percent in the three months ending Sept. 30, when compared to the same periods the previous year.

By MassDevice Staff
Devices & Diagnostics

Hologic to distribute Angiotech breast biopsy device

A new private-label deal will see Hologic Inc. distributing a soft tissue biopsy instrument manufactured by Angiotech Pharmaceuticals Inc. Angiotech Pharmaceuticals Inc. (NSDQ:ANPI) inked a three-year, private-label deal with Bedford, Mass.-based Hologic Inc. (NSDQ:HOLX). Under the terms of the agreement, Vancouver-based Angiotech will supply Hologic with its soft tissue biopsy device for breast biopsies. The […]

By MassDevice Staff
MedCity Influencers

Angiotech Pharma sells Lifespan vascular graft business for $2.8M

LeMaitre Vascular Inc. (NASDAQ:LMAT) picked up Angiotech Pharmaceuticals Inc.’s (NASDAQ:ANPI) Lifespan vascular graft business for $2.8 million and spiked a distribution deal Angiotech had with former Lifespan owner Edwards Lifesciences Corp. (NYSE:EW). Burlington, Massachusetts-based LeMaitre said it paid a multiple of 1.8 times the Lifespan revenues from the last 12 months for the vascular prosthesis, […]

By MassDevice Staff
MedCity Influencers

Former shareholders sue Angiotech Pharma for lying

A group representing former shareholders of Angiotech Pharmaceuticals Inc. (NSDQ:ANPI) subsidiary Quill Medical Inc. are suing both companies. QSR Holdings Inc. alleges that Angiotech concealed damaging information about the sales performance of a Quill product prior to Angiotech's acquisition of the company. It also alleges that Angiotech acted to deliberately reduce future milestone-related payments to QSR. Cleveland's Athersys is an Angiotech partner.

By MassDevice Staff
MedCity Influencers

Angiotech Pharmaceuticals struggles to reduce debt

Angiotech Pharmaceuticals Inc. (NSDQ:ANPI) deferred $9.7 million in interest payments on debt that were due Oct. 1, looking to "effectuate a transaction that would materially reduce the company's existing debt levels," the company said. Angiotech is working with Cleveland, Ohio-based Athersys to develop an adult stem cell therapy for heart attack patients.

By MassDevice Staff
News

In-vitro fertilization pioneer wins Nobel Prize (Morning Read)

Robert Edwards of Britain, an 85-year-old professor emeritus at the University of Cambridge who started working on in-vitro fertilization as early as the 1950s, won the 2010 Nobel Prize in medicine on Monday for developing the breakthrough that has helped millions of infertile couples worldwide have children, according to the Associated Press in the Washington Post.

By Mary Vanac
presented by